glp-1 receptor agonists should be avoided in patients with Impact of GLP- 1 Agonist Therapy High Risk for Sarcopenia | Current Nutrition Reports Glucagon-Like Peptide-1 Receptor Agonists for

Cosmetic effects like Ozempic face (a thinner, gaunt appearance from rapid fat loss in the face) and temporary hair shedding have also been reported

Type 2 diabetes and cancer: umbrella review of meta-analyses of observational studies

These effects were coupled to an amelioration in lipid metabolism and hepatic steatosis, which markedly exceeded the effect of single GLP-1RA treatment ( Oxyntomodulin, a gut-derived peptide hormone, activates both the GLP-1R and the GCGR, although, with reduced affinity compared to GLP-1 and glucagon, respectively

13 In these early-phase studies, mazdutide exhibited a favorable safety profile, with predominantly mild-to-moderate gastrointestinal adverse effects reported

With the 2026 Standards of Care increasingly shifting the focus toward cardio-renal outcomes, many clinicians are asking: how far can we go safely with GLP1 receptor agonists Read More

Morse, GLP-1s are definitely not a one-trick pony. What is GLP-1, and how do GLP-1 receptor agonists combat obesity and diabetes